Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma
Open Access
- 16 September 2023
- journal article
- research article
- Published by Springer Nature in npj Precision Oncology
- Vol. 7 (1) , 1-13
Abstract
As a highly lethal adenocarcinoma of the hepatobiliary system, outcomes for cholangiocarcinoma (CCA) patients remain prominently poor with a 5-year survival of <10% due to the lack of effective treatment modalities. Targeted therapeutics for CCA are limited and surgical resection of CCA frequently suffers from a high recurrence rate. Here we report two effective targeted therapeutics in this preclinical study for CCA. We first performed a quantitative and unbiased screening of cancer-related antigens using comparative flow cytometry in a panel of human CCA cell lines, and identified intercellular adhesion molecule-1 (ICAM1) as a therapeutic target for CCA. After determining that ICAM1 has the ability to efficiently mediate antibody internalization, we constructed two ICAM1 antibody-drug conjugates (ADCs) by conjugating ICAM1 antibodies to different cytotoxic payloads through cleavable chemical linkers. The efficacies of two ICAM1 ADCs have been evaluated in comparison with the first-line chemodrug Gemcitabine in vitro and in vivo, and ICAM1 antibodies coupled with warhead DX-8951 derivative (DXd) or monomethyl auristatin E (MMAE) elicit a potent and consistent tumor attenuation. In summary, this study paves the road for developing a promising targeted therapeutic candidate for clinical treatment of CCA.Keywords
This publication has 37 references indexed in Scilit:
- A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple MyelomaClinical Cancer Research, 2015
- Cohort profile: cholangiocarcinoma screening and care program (CASCAP)BMC Cancer, 2015
- Type I interferons in anticancer immunityNature Reviews Immunology, 2015
- ICAM-1 as a molecular target for triple negative breast cancerProceedings of the National Academy of Sciences, 2014
- Melanoma upregulates ICAM‐1 expression on endothelial cells through engagement of tumor CD44 with endothelial E‐selectin and activation of a PKCα–p38‐SP‐1 pathwayThe FASEB Journal, 2014
- Total Antibody Quantification for MMAE-Conjugated Antibody–Drug Conjugates: Impact of Assay Format and ReagentsBioconjugate Chemistry, 2013
- Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibodyBlood, 2013
- Intercellular adhesion molecule‐1 (ICAM‐1) expression correlates with oral cancer progression and induces macrophage/cancer cell adhesionInternational Journal of Cancer, 2013
- Antibody Conjugate Therapeutics: Challenges and PotentialClinical Cancer Research, 2011
- ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cellsEuropean Respiratory Journal, 1996